
LIGAND PHARMACEUTICALS
LGNDNASDAQTrading Snapshot
- Day Range
- $284.97 β $292.71
- 52-Week Range
- $137.14 β $326.63
- Volume
- $5.31B
- Avg Volume
- $5.00B
- Shares Outstanding
- 20.0M
- Next Earnings
- Sep 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $268M
- Last Q Revenue
- $64M
- P/E Ratio
- 38.7
- P/S Ratio
- 21.6x
- EPS (TTM)
- $7.42
- Dividend Yield
- β
Why Investors Own LGND
- βHigh-growth profile β revenue up +39.7% YoY with expanding US Equity exposure.
- βHealthy economics β 35% gross margin and 20% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About LIGAND PHARMACEUTICALS
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The companyβs comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
LIGAND PHARMACEUTICALS tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift LGND price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
LIGAND PHARMACEUTICALS announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.